This Article Full Text (PDF) All Versions of this Article: 1756283X09346794v1 2/6/323    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Bhat, Y. M. Articles by Ginsberg, G. G. Social Bookmarking                         What's this?

Endoscopic resection with ligation using a multi-band mucosectomy system in Barrett’s esophagus with high-grade dysplasia and intramucosal carcinoma

Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA ybhat{at}mednet.ucla.edu

Emma E. Furth

Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Colleen M. Brensinger

Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Gregory G. Ginsberg

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Background: Endoscopic therapy for early neoplasia in Barrett’s esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA].

Methods: A cohort of 65 consecutive patients from a single academic medical center, who underwent ER-L as part of endoscopic eradication therapy for BE with HGD/IMCA were studied. ER-L was performed after endoscopic mapping and endoscopic ultrasound (EUS). Subsequently, adjunctive ablative therapies including photodynamic therapy, argon plasma coagulation and radiofrequency ablation were applied to achieve complete eradication of all BE. Thereafter biopsy surveillance was performed per protocol. All patients were prescribed a proton-pump inhibitor. Main outcome measurements: Change in histopathological stage; eradication of BE and HGD/IMCA; adverse events.

Results: The median number of ER-L applications in each session was 4 (range 1-6) and the mean total number of ER-L sessions was 1.5. Compared with prior forceps biopsy, histopathology from the ER-L specimen changed in 24 (37.5%, p =<0.0001). With median follow-up of 15 months (range 8-42), complete and durable BE eradication was achieved with ER-L alone in 36 (60%) and the remainder with adjunctive ablation therapies. There were nine complications (four (6%) acute bleeding, five (7.5%) strictures, zero perforations).

Conclusions: ER-L without submucosal (SM) pre-injection is safe and effective when applied selectively for eradication of BE with HGD/IMCA. There is significant change in pathological stage after ER-L conferring a diagnostic and staging advantage. ER-L may be used adjunctively with ablation therapies.

Key Words: Barrett’s esophagus • early esophageal cancer • endoscopic treatment of Barrett’s esophagus

This version was published on November 1, 2009

Therapeutic Advances in Gastroenterology, Vol. 2, No. 6, 323-330 (2009)
DOI: 10.1177/1756283X09346794


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?